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Background
Non-occupational HIV post-exposure prophylaxis (nPEP)
has been prescribed in Switzerland for more than a dec-
ade. Large population-based analysis of nPEP over such a
period has rarely been studied.
Methods
We conducted a retrospective analysis of all nPEP requests
between 1998 and 2007 in a single nPEP reference center.
Global results as well as trend over time were analysed.
Summary of results
Number of nPEP requests increased from 20 to 191
(>850%) over the study period. Among 1,205 events,
51% were heterosexual exposure, 13% homosexual expo-
sure, 6% sexual assaults, and 23% needlestick and other
percutaneous injuries. Sixty-six percent of exposed
patients were males, 6% injection drug users, 3% com-
mercial sex workers, 14% clients of commercial sex work-
ers, and 5% cleaning personnel. HIV status of source
persons was positive in 23%. For the remaining 920,
active tracing allowed to test 313 persons and identified
11 undiagnosed HIV individuals (3.5%). nPEP was rec-
ommended for 990 events but could be avoided or inter-
rupted in 290 cases when the source was tested negative.
Out of 784 patients who started nPEP, 57% reported side-
effects, which led to treatment interruption in 52 cases.
There were two HIV seroconversions, none of which was
attributed to nPEP failure.
Conclusion
nPEP requests increased over time. Testing the source per-
son for HIV allowed to avoid nPEP in 29% of cases, and is
therefore paramount in the management of potential HIV
exposure. Furthermore, it allows active screening of high-
risk behaviour population for undiagnosed HIV infection,
as shown by our prevalence of 3.5%. This number may
justify nPEP prescription in cases where HIV status of the
source cannot be determined.
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